Bill to propose federal drug comparisons

Should the feds fund studies to compare drugs' effectiveness? The idea appears to be gaining traction. Two congressmen are readying legislation that would create an institute to systematically examine drugs and devices.

It's a controversial idea: Drug and device makers are naturally worried, but so are anti-big government types who fear that a British-style drug review board would interfere with consumer choice, physician autonomy, and market dynamics. But on the pro side of the ledger are some economists and business groups who think that this sort of research could cut healthcare spending by hundreds of billions annually.

- read the item at Pharmalot

Related Articles:
Pact adds cost effectiveness to drug study. Report
Where's the ROI on drug R&D budgets? Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.